Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small

Updated 06/21/2024

Status Not yet recruiting

Clinical Trial Summary

This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Non-Small Cell Lung Cancer(NSCLC)

Clinical Trial Details

NCT number	NCT05765877
Study type	Interventional
Source	Shandong Cancer Hospital and Institute
Contact	Pingping Song
Phone	18663776711
Email	SPP128@126.com
Status	Not yet recruiting
Phase	Phase 2
Start date	March 2023
Completion date	July 2025

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01712217` - A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib	Phase 1/Phase 2
	Not yet recruiting	`NCT06332755` - Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors	Phase 1
	Recruiting	`NCT02820116` - The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation	Phase 2
	Active, not recruiting	`NCT02667743` - Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC	Phase 3
	Recruiting	`NCT02036359` - Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca	Phase 2
	Completed	`NCT02603003` - the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs	Phase 1
	Active, not recruiting	`NCT01637597` - Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation	N/A
	Completed	`NCT05169801` - To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC	Phase 3